Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

Israel’s Kanabo Research aims this year to become the first cannabis company to list on London’s main stock market, as part of efforts to raise £4-million (US$4.8 million) for clinical trials and to launch over-the-counter products, its CEO said.

Cannabis companies have listed in Canada and Israel and lawyers say London has the potential to attract money from diverse sectors, including food and health, which can use cannabis as an ingredient.

Kanabo’s CEO Avihu Tamir said he sees better prospects in London than in more saturated markets, despite the upheaval caused by Britain’s looming departure from the European Union, and believes it is worth being a pioneer in overcoming regulatory hurdles.

Story continues below advertisement

“In this industry, the first-mover advantage is significant,” he said, adding that the first cannabis companies that listed in Canada remained the biggest.

He said Kanabo aimed to list in London in the final quarter of this year and he hoped it would be the first, but did not know how much competition it faced.

The London Stock Exchange said it couldn’t comment on potential listings.

In Canada, where the relaxation of cannabis laws culminated in legalization for recreational use in October, venture capital that would previously be attracted to small mining companies helped to drive a surge of new listings.

In Israel, medical cannabis is one of the fastest-growing sectors on the Tel Aviv stock exchange, prompting the Israeli regulator to warn in May that it could become an investment bubble.

Kanabo already has a promise of £1.4-million from Spinnaker Opportunities, a cash shell listed in London which has said it is looking for acquisitions.

Kanabo’s products are delivered through a vaping device, which has approval from the Israeli health ministry. It is also seeking to launch over-the-counter products in Germany and Britain, Tamir said.

Story continues below advertisement

Lawyers are cautious, though. While some cannabis-based products are available in shops in Britain, there are strict regulations and there is uncertainty over the extent to which laws will be relaxed.

“A lot of people are wanting to have a conversation about the sector, but investors need to tread carefully and take guidance to navigate what is a complex regulatory landscape,” SAID Claire O’Donnell, a partner at Norton Rose Fulbright.

London’s Alternative Investment Market (AIM) for growing companies has already had a listing in the sector. GW Pharmaceuticals, a developer of marijuana-based epilepsy treatments, was listed there from June 2001 to 2016.

The company is still listed on the U.S. Nasdaq and its shares have risen more than 40 per cent this year. It received a boost in July after the company’s marijuana-based epilepsy treatment Epidiolex won a positive recommendation for marketing approval from a European Medicines Agency (EMA) panel for use as an additional treatment for two types of seizures.

Related topics

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies